Telix Pharmaceuticals Limited receives R&D tax refund

Telix Pharmaceuticals Limited (ASX: TLX) announced that it had received an R&D tax refund of AU$17.25 million from the Australian Federal Government, regarding eligible R&D activities done by the company in the year ended 31 December 2021.

On 28 September 2021, Telix Pharmaceuticals Limited announced that it had received an expanded overseas finding from the Department of Industry, Science, Energy, and Resources which will allow the company to claim a Research and Development tax cash rebate, or deduction on eligible R&D investment, up to a gross amount of AU$139 million from the 2021 financial year through to 31 December 2027.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au